TY  - JOUR
AU  - Cañas, Amanda
AU  - López-Sánchez, Laura M
AU  - Peñarando, Jon
AU  - Valverde, Araceli
AU  - Conde, Francisco
AU  - Hernández, Vanessa
AU  - Fuentes, Elena
AU  - López-Pedrera, Chary
AU  - de la Haba-Rodríguez, Juan R
AU  - Aranda, Enrique
AU  - Rodríguez-Ariza, Antonio
PY  - 2016
DO  - 10.1016/j.bbadis.2016.02.005
SN  - 0006-3002
UR  - https://hdl.handle.net/10668/28262
T2  - Biochimica et biophysica acta
AB  - The monoclonal antibody trastuzumab against HER2/neu, which is overexpressed in 15-20% of breast cancers, has clinical efficacy but many patients do not respond to initial treatment or develop resistance during treatment. Nitric oxide (NO) regulates...
LA  - en
KW  - Apoptosis
KW  - Breast cancer
KW  - HER2/neu
KW  - Nitric oxide
KW  - S-nitrosoglutathione reductase
KW  - S-nitrosylation
KW  - Breast Neoplasms
KW  - Cell Survival
KW  - Drug Resistance, Neoplasm
KW  - Female
KW  - Homeostasis
KW  - Humans
KW  - MCF-7 Cells
KW  - Receptor, ErbB-2
KW  - S-Nitrosothiols
KW  - Trastuzumab
TI  - Altered S-nitrosothiol homeostasis provides a survival advantage to breast cancer cells in HER2 tumors and reduces their sensitivity to trastuzumab.
TY  - research article
VL  - 1862
ER  -